Stelara is a biologic that was approved for the treatment of psoriasis in 2009 and for the treatment of psoriatic arthritis in 2013.

What is Stelara?

Stelara (also known by its generic name ustekinumab) was approved by the FDA in September 2009 for the treatment of moderate-to-severe plaque psoriasis in patients ages 6 years and older. Stelara is also approved to treat patients 6 years and older with active psoriatic arthritis.

Stelara is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterward.

To learn more, please visit the Stelara website.

Biosimilars for Stelara

biosimilar is a medication that is highly similar to an existing FDA-approved biologic medicine (aka reference product). Biosimilars have the same strength, dosage, potential benefits, and side effects as the reference product and are administered the same way. Biosimilars still must be FDA-approved.

A mother and child lay in a tent and read a book together.

FDA Approves Stelara® for Pediatric Psoriasis Patients

The FDA has approved the use of Stelara® (ustekinumab) for use in pediatric patients.

Learn more
Illustrated graphic of people around a rocket ship and computer.

Advance Online

Get the latest news on new treatment options from NPF.

Stay up to date
A black girl running outside with a wooden toy plane in her hand.

FDA Approves Stelara® For Use in Pediatric Patients With PsA

An expanded approval gives a new treatment option to children with psoriatic arthritis.

Read more

Learn More About Your Treatment Options

The Patient Navigation Center is here to provide personalized information about your psoriasis and psoriatic arthritis treatment.

Contact a Patient Navigator today

Stay in the Know

Expert tips, can’t-miss events, and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity NavigatorCommunity Health Charities logo

Copyright © 1996-2023 National Psoriasis Foundation/USA

Duplication, rebroadcast, republication, or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).

NPF does not endorse or accept any responsibility for the content of external websites.

NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.